Stockreport

Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program

Neurogene Inc.  (NGNE) 
PDF NGN-401 is one of only three CBER programs chosen by FDANGN-401 was selected based on potential for clinical benefits and clinical development program readinessSTART Pro [Read more]